摘要
目的探讨白介素-17(IL-17)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)在慢加急性肝衰竭(ACLF)患者中的作用。方法选取2015年1月~2018年6月在本院住院治疗的59例肝损伤患者作为对照组,59例ACLF患者作为观察组。ACLF患者根据疾病分期进一步分为早期组(20例)、中期组(20例)、晚期组(19例)3组。采用流式细胞仪方法检测所有患者的血清IL-17、IL-6及TNF-α的浓度并进行比较。结果观察组血清IL-17、IL-6及TNF-α的浓度高于对照组,差异有统计学意义(P<0.05)。ACLF不同分期患者的血清IL-17、IL-6及TNF-α浓度组间比较,差异有统计学意义(P<0.05);其中,晚期组的血清IL-17、IL-6及TNF-α浓度高于中期组及早期组,中期组血清IL-17、IL-6及TNF-α的浓度高于早期组,差异均有统计学意义(P<0.05)。结论IL-17、IL-6、TNF-α参与ACLF的发生与发展过程,是促进ACLF肝功能恶化的因素,并且其浓度高低与ACLF的分期相关。
Objective To investigate the effects of interleukin-17(IL-17),IL-6 and tumor necrosis factor-α(TNF-α)in patients with with acute on chronic liver failure(ACLF).Methods A total of 59 patients with liver injury hospitalized in our hospital from January 2015 to June 2018 were selected as control group and 59 patients with ACLF as observation group.ACLF patients were further divided into early group(20 cases),middle group(20 cases)and late group(19 cases)according to disease stages.The concentrations of serum IL-17,IL-6 and TNF-αin all patients were detected by flow cytometry and compared.Results The concentrations of serum IL-17,IL-6 and TNF-αin the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of serum IL-17,IL-6 and TNF-αin ACLF patients with different stages were different between groups(P<0.05).Among them,the concentrations of serum IL-17,IL-6 and TNF-αin the late group were higher than those in the middle group and the early group,and the concentrations of serum IL-17,IL-6 and TNF-αin the middle group were higher than those in the early group,the differences were statistically significant(P<0.05).Conclusion IL-17,IL-6 and TNF-αparticipate in the occurrence and development of ACLF,which is a factor to promote the deterioration of ACLF liver function,and their concentrations are related to the stages of ACLF.
作者
朱立娜
唐源
黄初军
赵秋燕
尹春萍
ZHU Li-na;TANG Yuan;HUANG Chu-jun;ZHAO Qiu-yan;YIN Chun-ping(Department of Gastroenterology,Qujing First People′s Hospital,Yunnan Province,Qujing 655000,China)
出处
《中国当代医药》
2019年第36期44-46,共3页
China Modern Medicine
基金
云南省曲靖市第一人民医院院级科研课题（2019YJKT10）
